UK markets close in 1 hour 57 minutes
  • FTSE 100

    -59.76 (-0.85%)
  • FTSE 250

    -270.19 (-1.50%)
  • AIM

    -7.26 (-0.87%)

    +0.0033 (+0.29%)

    -0.0016 (-0.15%)

    -22.68 (-0.13%)
  • CMC Crypto 200

    +3.72 (+0.86%)
  • S&P 500

    -3.28 (-0.09%)
  • DOW

    -59.32 (-0.20%)

    +0.82 (+1.04%)

    -2.00 (-0.12%)
  • NIKKEI 225

    -722.28 (-2.66%)

    -78.13 (-0.44%)
  • DAX

    -9.82 (-0.08%)
  • CAC 40

    -7.93 (-0.14%)

A GlycoMimetics, Inc. (NASDAQ:GLYC) insider increased their holdings last year

·3-min read

From what we can see, insiders were net buyers in GlycoMimetics, Inc.'s (NASDAQ:GLYC ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.

See our latest analysis for GlycoMimetics

GlycoMimetics Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Independent Director Patricia S. Andrews for US$82k worth of shares, at about US$2.05 per share. That means that even when the share price was higher than US$0.63 (the recent price), an insider wanted to purchase shares. Their view may have changed since then, but at least it shows they felt optimistic at the time. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when an insider has purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price. Patricia S. Andrews was the only individual insider to buy during the last year.

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!


GlycoMimetics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Are GlycoMimetics Insiders Buying Or Selling?

The last three months saw some GlycoMimetics insider selling. Insiders only netted US$9.2k selling shares, in that period. It's not great to see insider selling, nor the lack of recent buyers. But the volume sold is so low that it really doesn't bother us.

Insider Ownership of GlycoMimetics

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data suggests GlycoMimetics insiders own 2.1% of the company, worth about US$709k. We consider this fairly low insider ownership.

So What Does This Data Suggest About GlycoMimetics Insiders?

We did not see any insider buying in the last three months, but we did see selling. But given the selling was modest, we're not worried. However, our analysis of transactions over the last year is heartening. We'd like to see bigger individual holdings. However, we don't see anything to make us think GlycoMimetics insiders are doubting the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing GlycoMimetics. To that end, you should learn about the 4 warning signs we've spotted with GlycoMimetics (including 1 which is a bit unpleasant).

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.